Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?

We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Lyell Immunopharma, Inc. (NASDAQ:LYEL) stands against other cheapest stocks insiders are buying in March.

After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, while the NASDAQ Composite rose 0.2%. Monday’s enthusiasm came from hopes of looser U.S. tariffs.

Investors mostly ignored the March consumer confidence data released on Tuesday, which showed a sharp decline in U.S. consumers’ short-term outlook on income, business, and job conditions, reports CNBC.

“Sentiment continues to wane among investors, consumers and businesses as economic concerns and economic policy uncertainty takes its toll,” said Bret Kenwell, U.S. investment analyst at eToro. “Until there’s more certainty on the tariff and macro front, sentiment and confidence remain vulnerable.”

As investors navigate daily market changes, uncertainty remains a persistent factor. Insider trading tends to attract attention during these periods, as purchases of company stock by executives may suggest optimism about the company’s future. However, insider selling doesn’t necessarily signal a lack of confidence—it could simply be for personal financial reasons or to diversify holdings. Many executives use pre-established plans, such as 10b5-1, to maintain transparency. While insider trading can provide useful insights, it’s important to evaluate it alongside a company’s financial stability, broader market trends, and industry dynamics.

What are some of the cheapest stocks insiders have been buying this month so far? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least two insiders had purchased shares in March. From there, we ranked the 10 stocks with the lowest average price per share.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

With each stock, we note the average price per share of these purchases and the stock’s market capitalization.

Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Market Capitalization: $165.09 million

Lyell Immunopharma is a clinical-stage cell therapy company focused on developing CAR T-cell therapies for hematologic malignancies and solid tumors. The company is advancing therapies using innovative approaches to improve T-cell resistance to exhaustion and enhance antitumor activity. Lyell is developing the IMPT-314 dual-targeting CAR T-cell product for aggressive relapsed/refractory lymphoma and has a preclinical solid tumors program.

The company reported a net loss of $191.9 million for the fourth quarter and $343.0 million for the year ended December 31, 2024, compared to a net loss of $52.9 million for the fourth quarter and $234.6 million for the year in 2023. Research and development (R&D) expenses were $48.7 million and $171.6 million for the fourth quarter and full year of 2024, respectively, compared to $47.0 million and $182.9 million for the same periods in 2023. Cash, cash equivalents and marketable securities as of December 31, 2024 were $383.5 million compared to $562.7 million as of December 31, 2023. Lyell believes that its cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into 2027.

In March, two insiders, including the CFO, purchased approximately $312,752 worth of Lyell Immunopharma shares at an average price of $0.59 per share. The stock now trades at $0.56 per share, having dropped 12.62% year-to-date and 70.87% over the past 12 months.

StockAnalysis reports that two analysts have rated Lyell Immunopharma stock as “Sell” with a price target of $1.0. The average price target suggests a 78.89% upside from the latest price.

Overall, LYEL ranks 6th on our list of cheapest stocks insiders are buying in March. While we acknowledge the potential of LYEL our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LYEL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.